4BB — 4Basebio Share Price
Last Trade - 00:00- £84.99m
- £86.71m
- £0.46m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 0.2 | 0.46 | n/a | n/a | 128.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
4basebio PLC is a United Kingdom-based specialist life sciences company. The Company is engaged in developing next generation gene therapy technologies and solutions. The Company is focused on supplying therapeutic deoxyribonucleic (DNA) for gene therapies and DNA vaccines and also for providing solutions for delivery of the DNA based products to patients. The Company focuses to manufacture and supply synthetic DNA for research, therapeutic and pharmacological use. Its TruePrime DNA amplification technology is a primer free DNA amplification method using enzymes. Its Hermes is a non-viral delivery platform that can be used to deliver various payloads, ranging from DNA to small interfering ribonucleic acid (siRNA), as well as protein cargoes. It also offers a messenger ribonucleic acid (mRNA) production service from the DNA template it makes. It offers a range of services including production of synthetic DNA and RNA payloads, design and assembly of payloads in nanoparticles.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- January 1st, 1970
- Incorporated
- January 1st, 1970
- Public Since
- January 1st, 1970
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 12,317,473
- Address
- 25 Norman Way, Over, CAMBRIDGE, CB24 5QE
- Web
- https://www.4basebio.com/
- Phone
- +44 1223967943
- Auditors
- Crowe U.K. LLP
Latest News for 4BB
Upcoming events for 4BB
Similar to 4BB
ARECOR THERAPEUTICS ORD
London Stock Exchange
BIOVENTIX ORD
London Stock Exchange
BIVICTRIX THERAPEUTICS ORD
London Stock Exchange
C4X DISCOVERY HOLDINGS ORD
London Stock Exchange
CIZZLE BIOTECHNOLOGY HOLDINGS ORD
London Stock Exchange
FAQ
As of Today at 11:30 UTC, shares in 4Basebio are trading at 690.00p. This share price information is delayed by 15 minutes.
Shares in 4Basebio last closed at 690.00p and the price had moved by over the past 365 days. In terms of relative price strength the 4Basebio share price has matched the FTSE All Share Index by over the past year.
There is no consensus recommendation for this security.
4Basebio does not currently pay a dividend.
4Basebio does not currently pay a dividend.
4Basebio does not currently pay a dividend.
To buy shares in 4Basebio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 690.00p, shares in 4Basebio had a market capitalisation of £84.99m.
Here are the trading details for 4Basebio:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: 4BB
Based on an overall assessment of its quality, value and momentum 4Basebio is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4Basebio. Over the past six months, its share price has outperformed the FTSE All Share Index by +39.22%.
As of the last closing price of 690.00p, shares in 4Basebio were trading +66.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 4Basebio.
We do not have data on 4Basebio's directors
We do not have data on 4Basebio's shareholders